GN Hearing introduces Interton Move, an essential hearing aid portfolio to help people get more out of life
3.5.2021 10:00:00 EEST | Business Wire | Press release
GN Hearing, the global leader in hearing aid innovation, today unveils Interton Move, the newest addition to its leading portfolio of hearing solutions that caters to all user needs. Interton Move makes great sound quality and best-in-class connectivity more accessible, helping hearing care professionals meet the diverse needs of people living with hearing loss.
The lineup of 10 essential hearing aids represents the biggest upgrade in the history of Interton. People from across the hearing loss spectrum can now get more out of life with greater choice than ever before. Most importantly, people can now feel confident when communicating with friends and family as they can focus on what they want to hear. They benefit from improved listening comfort in different environments, made possible thanks to a new, faster, more powerful sound processing platform. The launch also presents new rechargeability options and full smartphone support with direct audio streaming and an app for personalization. These vital elements result in high-quality, yet affordable hearing care with all the benefits of GN’s leading and proven technology.
Globally, 430 million people live with hearing loss and only 1 in 5 people who could benefit from hearing aids actually use them.1 Untreated hearing loss has wide-reaching impacts on a person’s quality of life and happiness. As hearing loss can be perceived by some as a small problem and something to ignore or put up with, hearing aids may be seen as an overwhelming solution. With the new Interton Move portfolio, hearing care professionals can now offer simple and straightforward hearing care to more people than ever before.
GN Hearing CEO and President, Gitte Aabo, explains: “At GN Hearing, we want to make life sound better for every person with hearing loss. Treating hearing loss can radically transform an individual’s life, as they can hear more and return to doing what they love. With the launch of Interton Move, we’re pleased to support the crucial role that hearing care professionals play in helping people access the hearing care they need.”
The extensive portfolio includes a mini rechargeable Receiver-in-Ear (RIE), a mini Behind-the-Ear (BTE), custom hearing aids, and even a ‘Super Power’ option for profound hearing loss. The rechargeable RIE model and its matching desktop charger provide freedom from batteries and up to 30 hours of use on a single charge.
All Interton Move users can enjoy high-quality streaming of calls, music, and other audio directly from compatible Apple and AndroidTM devices. Meanwhile, the Interton Sound smartphone app enables users to personalize their hearing experience and connect to GN’s extensive range of wireless accessories.
All aspects of the fitting and onboarding process have been upgraded to improve the user experience and to ensure that the start of a person’s hearing journey is as seamless as possible. To make consulting easier for hearing care professionals, the Interton Fitting Software follows the same workflow as all other GN Hearing solutions.
Interton Move will roll out globally and be available in the first countries from May 2021.
NOTES TO EDITORS
About Interton
Interton was founded in Germany in 1962 and is part of the GN Group. Interton hearing aids are designed in Denmark and powered by pioneering technology that has transformed the sound quality, functionality, and comfort of hearing aids.
Visit our homepage interton.com – and connect with us on Facebook.
About GN Group
The GN Group enables people to Hear More, Do More and Be More through its intelligent hearing, audio and video collaboration solutions. Inspired by people and driven by our innovation leadership, we leverage technological synergies between our hearing and audio divisions to deliver unique and increasingly individualized user experiences in our products and solutions.
150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, sound and video processing, wireless technology, miniaturization and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, Beltone, Interton, Jabra, BlueParrott and FalCom in 100 countries. Founded in 1869, the GN Group employs 6,500 people and is listed on Nasdaq Copenhagen (GN.CO).
Visit our homepage GN.com and connect with us on LinkedIn and Facebook.
© 2021 GN Hearing A/S. All rights reserved. Interton is a trademark of GN Hearing A/S. Apple, the Apple logo, iPhone, iPad and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries. Android is a trademark of Google LLC.
|
1 WHO: Deafness and hearing loss: https://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss. Accessed on April 12, 2021. |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005229/en/
Contact information
Press and the media
Marie Schleimann Nordlund
Head of PR & Communication
Tel: +45 31 26 37 34
Lars Otto Andersen-Lange
Head of Media Relations & Public Affairs
Tel: +45 45 75 02 55
Investors and analysts
Henriette Wennicke
VP – Investor Relations & Treasury
Tel: +45 45 75 03 33
Rune Sandager
Director – Investor Relations & Treasury
Tel: +45 45 75 92 57
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom